Amneal EVP sells 146,403 shares of stock

Amneal Pharmaceuticals, Inc. Executive Vice President Nikita Shah reported a sale of 146,403 shares of Class A Common Stock on August 12, 2026.

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. Executive Vice President Nikita Shah reported a sale of 146,403 shares of Class A Common Stock on August 12, 2026. The sale was executed at a weighted average price of $17.51 per share, with individual trade prices ranging from $17.40 to $17.67 per share. Following this transaction, Shah directly holds 253,390 shares of Amneal Class A Common Stock.

Insider Trade Summary

Net Seller: 146,403 shares

Net Sell 1 txn

Insider Shah Nikita

Role Executive Vice President

Sold 146,403 shs ($2.56M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1	146,403	$17.51	$2.56M

Holdings After Transaction: Class A Common Stock — 253,390 shares (Direct)

Footnotes (1)

1. F1. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

Key Figures

Shares sold: 146,403 shares Weighted average sale price: $17.51 per share Sale price range: $17.40–$17.67 per share +2 more

5 metrics

Shares sold 146,403 shares Class A Common Stock sold on August 12, 2026

Weighted average sale price $17.51 per share Weighted average price for 146,403 shares sold

Sale price range $17.40–$17.67 per share Range of prices for multiple sale transactions

Shares held after transaction 253,390 shares Direct ownership of Class A Common Stock after sale

Net shares sold 146,403 shares Net sell shares reported in transaction summary

Key Terms

weighted average price, Class A Common Stock, open market or private transaction

3 terms

weighted average price financial

"The price included in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Class A Common Stock financial

"security_title: Class A Common Stock in the reported sale."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Amneal Pharmaceuticals (AMRX) report for Nikita Shah?

Amneal Pharmaceuticals reported that Executive Vice President Nikita Shah sold 146,403 shares of Class A Common Stock on August 12, 2026. After this open-market sale, Shah directly holds 253,390 shares of Amneal Class A Common Stock.

At what price were the AMRX shares sold by Executive Vice President Nikita Shah?

The reported sale used a weighted average price of $17.51 per share for 146,403 shares. Individual trades occurred at prices ranging from $17.40 to $17.67 per share, as disclosed in the Form 4 footnote.

How many Amneal Pharmaceuticals (AMRX) shares does Nikita Shah own after the reported sale?

Following the August 12, 2026 transaction, Executive Vice President Nikita Shah holds 253,390 shares of Amneal Class A Common Stock. This figure reflects the direct ownership position after selling 146,403 shares.

Was the AMRX insider sale by Nikita Shah a buy or sell transaction?

The Form 4 filing shows a sale of Amneal Class A Common Stock by Executive Vice President Nikita Shah. The transaction code is “S”, indicating an open-market or private sale of 146,403 shares.

Did the Amneal Pharmaceuticals (AMRX) Form 4 involve derivatives or only common stock?

The reported transaction involves only Class A Common Stock. The Form 4 lists no derivative transactions in the derivative security section, and the sale relates solely to non-derivative common shares.

How many total shares were sold by Nikita Shah in the latest AMRX Form 4?

The filing reports that Executive Vice President Nikita Shah sold 146,403 shares of Amneal Pharmaceuticals Class A Common Stock. The weighted average sale price was $17.51 per share, with trades between $17.40 and $17.67.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/13/2026 - 04:22 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shah Nikita

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BLVD.

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/12/2026		S		146,403	D	$17.51(1)	253,390	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)